A team of Greenberg Traurig attorneys recently represented Intec Pharma Ltd. (NASDAQ and TASE: NTEC) on the closing of its offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the underwriters of their over-allotment option in the amount of 1,594,500 ordinary shares, for gross proceeds of approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Intec Pharma intends to use the net proceeds from the offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company’s leading product candidate for the indication of treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, for working capital and for general corporate purposes.
The GT Deal Team included:
Robert Grossman, Corporate & Securities, (Miami); Joshua Samek, Corporate & Securities (Miami); Ilya Ross, Corporate & Securities (Boston); Eliott Rimon, Corporate & Securities, (Miami); Barry Schindler, IP-Prosecution, (New Jersey); Natalie Salem, IP-Prosecution, (Boston); Seth Entin, Tax, (Miami); and Ephraim Schmeidler, Corporate & Securities, (Tel Aviv).
Read more: